Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2016

View Archived Issues

miRagen Therapeutics and the ALS Association receive grant to develop ALS therapy

High endostatin levels may provide protective effect against cardiovascular events

Phase I study determines regimen for palbociclib with 5-fluorouracil in advanced solid tumors

Terumo launches HeartSheet in Japan

EpimAb Biotherapeutics announces agreement with Innovent Biologics

Protalix BioTherapeutics initiates global phase III study of PRX-102 in Fabry disease

GlaxoSmithKline discloses NAD-dependent SIRT1 activators

Medgenics collaborates with Kyowa Hakko Kirin on anti-LIGHT monoclonal antibody for pediatric IBD

Takeda Pharmaceutical and Roivant Sciences form Myovant Sciences

GeoVax begins HBV vaccine development program

Seres Therapeutics signs agreement with the Mayo Clinic

RealStar Zika virus test available in U.S.

Ocular Therapeutix's phase III trial of Dextenza does not meet primary endpoint

Adamis Pharmaceuticals receives FDA response on Epinephrine Injection

FDA approves Allergan's FDC Byvalson for hypertension

FDA requests further data to enable review of eteplirsen NDA

Scientists identify two novel mutations causing type I hyperlipoproteinemia

Vonosap and Vonopion packs launched in Japan for H. pylori eradication

TRX-518 is safe in patients with advanced solid tumors

Fusion peptide of HIV-1 as target for vaccine design

Targeting kynurenine pathway as promising therapeutic strategy for neurodegenerative disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...